Get started
Author

Richard Nicoletti

Subtype-specific genomic alterations define new targets for soft-tissue sarcoma therapy
2010 · Jordi Barretina, Barry S Taylor, et al. · Nature Genetics · 735
Drug-sensitive FGFR2 mutations in endometrial carcinoma
2008 · Amit Dutt, Helga B. Salvesen, et al. · Proceedings of the National Academy of Sciences · 345
Plasma growth differentiation factor 15 is associated with weight loss and mortality in cancer patients
2015 · Lorena Lerner, Teresa G. Hayes, et al. · Journal of Cachexia Sarcopenia and Muscle · 206
PDF
MAP3K11/GDF15 axis is a critical driver of cancer cachexia
2015 · Lorena Lerner, Julie Tao, et al. · Journal of Cachexia Sarcopenia and Muscle · 188
PDF
Neuregulin 1 Expression Is a Predictive Biomarker for Response to AV-203, an ERBB3 Inhibitory Antibody, in Human Tumor Models
2014 · Kristan Meetze, Sylvie Vincent, et al. · Clinical Cancer Research · 57
Growth differentiating factor-15 (GDF-15): A potential biomarker and therapeutic target for cancer-associated weight loss
2016 · Lorena Lerner, Jeno Gyuris, et al. · Oncology Letters · 55
PDF
23814, an Inhibitory Antibody of Ligand-Mediated Notch1 Activation, Modulates Angiogenesis and Inhibits Tumor Growth without Gastrointestinal Toxicity
2015 · Theresa Proia, Feng Jiang, et al. · Molecular Cancer Therapeutics · 8
Abstract 1153: Effective treatment of cancer associated cachexia by AV-380, a GDF15 inhibitory antibody
2015 · Lorena Lerner, Nianjun Tao, et al. · Cancer Research · 5
Abstract 4650: From bench to bedside: are cytokines still relevant biomarkers for staging cancer cachexia.
2013 · Antonio Vigano, Lorena Lerner, et al. · Cancer Research · 3
Abstract 3504: Plasma growth differentiating factor-15 (GDF-15) and other inflammatory markers are associated with weight loss and poor prognosis in cancer patients.
2013 · Lerner Lorena, Teresa Hayes, et al. · Cancer Research · 2
Relationship of hypoxia signature with variant subgroup of clear cell renal cell carcinoma (ccRCC) and its association with clinical activity on tivozanib hydrochloride.
2013 · Murray Owen Robinson, Bin Feng, et al. · Journal of Clinical Oncology · 1
Supplementary Figure Legends from 23814, an Inhibitory Antibody of Ligand-Mediated Notch1 Activation, Modulates Angiogenesis and Inhibits Tumor Growth without Gastrointestinal Toxicity
2023 · Theresa Proia, Feng Jiang, et al.
Supplementary Materials and Methods from 23814, an Inhibitory Antibody of Ligand-Mediated Notch1 Activation, Modulates Angiogenesis and Inhibits Tumor Growth without Gastrointestinal Toxicity
2023 · Theresa Proia, Feng Jiang, et al.
Supplementary Figures S1-3 and Table S1 from 23814, an Inhibitory Antibody of Ligand-Mediated Notch1 Activation, Modulates Angiogenesis and Inhibits Tumor Growth without Gastrointestinal Toxicity
2023 · Theresa Proia, Feng Jiang, et al.
Supplementary Figure Legends from 23814, an Inhibitory Antibody of Ligand-Mediated Notch1 Activation, Modulates Angiogenesis and Inhibits Tumor Growth without Gastrointestinal Toxicity
2023 · Theresa Proia, Feng Jiang, et al.
Supplementary Figures S1-3 and Table S1 from 23814, an Inhibitory Antibody of Ligand-Mediated Notch1 Activation, Modulates Angiogenesis and Inhibits Tumor Growth without Gastrointestinal Toxicity
2023 · Theresa Proia, Feng Jiang, et al.
Supplementary Materials and Methods from 23814, an Inhibitory Antibody of Ligand-Mediated Notch1 Activation, Modulates Angiogenesis and Inhibits Tumor Growth without Gastrointestinal Toxicity
2023 · Theresa Proia, Feng Jiang, et al.
Data from 23814, an Inhibitory Antibody of Ligand-Mediated Notch1 Activation, Modulates Angiogenesis and Inhibits Tumor Growth without Gastrointestinal Toxicity
2023 · Theresa Proia, Feng Jiang, et al.
Data from 23814, an Inhibitory Antibody of Ligand-Mediated Notch1 Activation, Modulates Angiogenesis and Inhibits Tumor Growth without Gastrointestinal Toxicity
2023 · Theresa Proia, Feng Jiang, et al.
Data from Neuregulin 1 Expression Is a Predictive Biomarker for Response to AV-203, an ERBB3 Inhibitory Antibody, in Human Tumor Models
2023 · Kristan Meetze, Sylvie Vincent, et al.
Supplementary Materials and Methods, Figure Legends from Neuregulin 1 Expression Is a Predictive Biomarker for Response to AV-203, an ERBB3 Inhibitory Antibody, in Human Tumor Models
2023 · Kristan Meetze, Sylvie Vincent, et al.
Supplementary Figures 1 - 4, Tables 1 - 2 from Neuregulin 1 Expression Is a Predictive Biomarker for Response to AV-203, an ERBB3 Inhibitory Antibody, in Human Tumor Models
2023 · Kristan Meetze, Sylvie Vincent, et al.
Data from Neuregulin 1 Expression Is a Predictive Biomarker for Response to AV-203, an ERBB3 Inhibitory Antibody, in Human Tumor Models
2023 · Kristan Meetze, Sylvie Vincent, et al.
Supplementary Figures 1 - 4, Tables 1 - 2 from Neuregulin 1 Expression Is a Predictive Biomarker for Response to AV-203, an ERBB3 Inhibitory Antibody, in Human Tumor Models
2023 · Kristan Meetze, Sylvie Vincent, et al.
PDF
Supplementary Materials and Methods, Figure Legends from Neuregulin 1 Expression Is a Predictive Biomarker for Response to AV-203, an ERBB3 Inhibitory Antibody, in Human Tumor Models
2023 · Kristan Meetze, Sylvie Vincent, et al.
Works count: 34
Citation count: 1,605
H-index: 7
I10-index: 6
Year
Topic
Type